Literature DB >> 11960382

The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.

Marc B Godfried1, Monique Veenstra, Peter v Sluis, Kathy Boon, Ronald v Asperen, Marie Christien Hermus, Barbara D C v Schaik, Tom P A Voûte, Manfred Schwab, Rogier Versteeg, Huib N Caron.   

Abstract

Gain of chromosome 17q material is the most frequent genetic abnormality in neuroblastomas. The common region of gain is at least 375 cR large, which has precluded the identification of genes with a role in neuroblastoma pathogenesis. Neuroblastoma also frequently show amplification of the N-myc oncogene, which correlates closely with 17q gain. Both events are strong predictors of unfavorable prognosis. To identify genes that are part of the N-myc downstream pathway, we constructed SAGE libraries of an N-myc transfected and a control cell line. This identified the chromosome 17q genes nm23-H1 and nm23-H2 as being 6-10 times induced in the N-myc expressing cells. Northern and Western blot analysis confirmed this up-regulation. Time-course experiment shows that both genes are induced within 4 h after N-myc is switched on. Furthermore, we demonstrate also that c-myc can up-regulate nm23-H1 and nm23-H2 expression. Neuroblastoma tumor and cell line panels reveal a striking correlation between N-myc amplification and mRNA and protein expression of both nm23 genes. We show that the nm23 genes are located at the edge of the common region of chromosome 17q gain previously described in neuroblastoma cell lines. Our findings suggest that nm23-H1 and nm23-H2 expression is increased by 17q gain in neuroblastoma and can be further up-regulated by myc overexpression. These observations suggest a major role for nm23-H1 and nm23-H2 in tumorigenesis of unfavorable neuroblastomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960382     DOI: 10.1038/sj.onc.1205259

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

Review 1.  Commentary: nm23, a metastasis suppressor gene with a tumor suppressor gene aptitude?

Authors:  Daniela Lombardi
Journal:  J Bioenerg Biomembr       Date:  2006-08       Impact factor: 2.945

2.  Aggregation of the neuroblastoma-associated mutant (S120G) of the human nucleoside diphosphate kinase-A/NM23-H1 into amyloid fibrils.

Authors:  Florian Georgescauld; Raimon Sabaté; Alba Espargaró; Salvador Ventura; Stéphane Chaignepain; Marie-Lise Lacombe; Ioan Lascu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-04-12       Impact factor: 3.000

3.  An overview of neuroblastoma cell lineage phenotypes and in vitro models.

Authors:  Sheron Campos Cogo; Thatyanne Gradowski Farias da Costa do Nascimento; Fernanda de Almeida Brehm Pinhatti; Nilton de França Junior; Bruna Santos Rodrigues; Luciane Regina Cavalli; Selene Elifio-Esposito
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-12

Review 4.  Oncogenic Epstein-Barr virus recruits Nm23-H1 to regulate chromatin modifiers.

Authors:  Saurabh Pandey; Erle S Robertson
Journal:  Lab Invest       Date:  2017-10-16       Impact factor: 5.662

5.  Mechanisms of non-metastatic 2 (NME2)-mediated control of metastasis across tumor types.

Authors:  Ram Krishna Thakur; Vinod Kumar Yadav; Pankaj Kumar; Shantanu Chowdhury
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-10       Impact factor: 3.000

Review 6.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

7.  Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.

Authors:  Derek M Murphy; Patrick G Buckley; Kenneth Bryan; Sudipto Das; Leah Alcock; Niamh H Foley; Suzanne Prenter; Isabella Bray; Karen M Watters; Desmond Higgins; Raymond L Stallings
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

8.  NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma.

Authors:  Choon-Yee Tan; Christina L Chang
Journal:  Lab Invest       Date:  2017-10-09       Impact factor: 5.662

9.  Expression profiling of favorable and unfavorable neuroblastomas.

Authors:  Eiso Hiyama; Keiko Hiyama; Hiroaki Yamaoka; Taijiro Sueda; C Patrik Reynolds; Takashi Yokoyama
Journal:  Pediatr Surg Int       Date:  2003-12-23       Impact factor: 1.827

10.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.